SEENERGIE
Unleash Human Potential
ARA 290
By acting as an innate repair receptor (IRR) agonist, it triggers anti-inflammatory and tissue repair pathways, and supports cellular regeneration.
Active ingredient:
n/a
Molecular formula:
C51H84N16O21
Molecular weight:
1257.3 g/mol
Intake:
Injection
ARA 290
Active ingredient:
n/a
Molecular formula:
C51H84N16O21
Molecular weight:
1257.3 g/mol
Intake:
Injection
What is
ARA 290
Could It Offer a Solution? ARA-290 is an 11-amino acid linear peptide acting as an innate repair receptor (IRR) agonist. The IRR consists of the erythropoietin receptor and the beta-common (CD131) receptor, simultaneously triggering anti-inflammatory and tissue repair pathways.
Experimental evidence suggests that following peripheral nerve injury, the IRR becomes upregulated in the spinal cord, influencing the neurogenic inflammatory response.
Focusing on the innate repair receptor to address neuropathy: In studies, ARA290 has demonstrated efficacy in preclinical disease models, including neuropathy, without associated adverse effects. In these models, the peptide has been found to transform a pro-inflammatory, tissue-damaging environment into one that promotes healing and repair.
Benefits
- Wound Healing
- Cardiovascular Health
- Neuropathic Pain Relief
- Anti-inflammatory Properties
- Improved Insulin Sensitivity
- Reduction in Chronic Fatigue
- Tissue Repair and Protection
- Improved Quality of Life in Sarcoidosis Patients
Protocols
- Content and Potency
Provided as a 20mg lyophilized vial
- Suggested Dosage
- Initiation: ARA 290 therapy is initiated to support anti-inflammatory processes, enhance tissue repair, and improve overall health by modulating erythropoietin receptors.
- Initial Dose: Begin with 2 mg (0.2 ml or 20 units) subcutaneously four times per week for the first two weeks to assess tolerance and minimize potential side effects.
- Titration: If well tolerated, increase the dose to 4 mg (0.4 ml or 40 units) subcutaneously four times per week after the initial two-week period.
- Maintenance: Maintain the dose at 4 mg (0.4 ml or 40 units) subcutaneously four times per week for ongoing support in anti-inflammatory processes and tissue repair.
- Duration: ARA 290 is administered four times per week.
- Weeks 1-2: 2 mg (0.2 ml or 20 units) of ARA 290 four times per week
- Week 3 and onwards: 4 mg (0.4 ml or 40 units) of ARA 290 four times per week
*Provided as a standard protocol, dose may vary depending on the condition of the patient.
*The dosage of ARA 290 may be adjusted based on the individual’s response, medical history, and specific treatment goals.
- Restrictions
- Known hypersensitivity to ARA 290 or any component of the formulation.
- Not recommended for use during pregnancy or breastfeeding unless specifically advised by a healthcare provider.
- Patients with severe renal or hepatic impairment should consult with their healthcare provider before starting this treatment.
- Caution in patients with a history of autoimmune diseases.
- Requirements
- Regular monitoring of inflammatory markers and overall health to assess the effectiveness of the treatment.
- Periodic assessments to check for any adverse effects and to adjust the treatment as necessary.
- Consultation with a healthcare professional before starting ARA 290 to ensure it is appropriate for the patient’s health condition.
- Patients should maintain a healthy lifestyle, including proper diet and exercise, to support the effectiveness of the treatment.
Procedure
- ARA 290
Reconstitution
- Draw 2 ml of sterile water for injection into a syringe.
- Inject the sterile water into a vial containing 20 mg of ARA 290 peptide.
- Gently swirl the vial until the peptide is fully dissolved.
- Administration
- Remove the cap from a tuberculin syringe.
- Draw the reconstituted ARA 290 solution into the syringe to the required dosage (0.2 ml or 20 units initially, 0.4 ml or 40 units after titration).
- Clean the selected injection site with an alcohol swab.
- Pinch the sanitized skin and insert the needle at a 90-degree angle.
- Administer the injection subcutaneously four times per week.
- For next usage
- Store the remaining ARA 290 solution in the refrigerator at 2-8°C.
- Before the next use, clean the vial top with an alcohol swab.
- Use a new syringe for each subcutaneous administration.
- Ensure to rotate injection sites (abdomen, thigh, or upper arm) to minimize skin irritation.
- Monitor for any unusual symptoms and report them to a healthcare provider immediately.
Clinical Research
Study:
ARA-290 for Neuropathic Pain and Inflammation
Source:
Molecular Medicine, Peptide Sciences, ResearchGate
Results:
ARA-290 is a non-erythropoietic peptide derived from erythropoietin that has shown significant promise in treating neuropathic pain and inflammation. It is primarily administered via subcutaneous injection, making it a suitable vial peptide for clinical use.
ARA-290 acts by binding to the innate repair receptor (IRR), which triggers anti-inflammatory and tissue-protective pathways. This interaction helps in reducing neuropathic pain, promoting tissue repair, and improving metabolic control.
Neuropathic Pain: In a double-blind, placebo-controlled trial, patients with sarcoidosis-associated small nerve fiber loss who received ARA-290 showed significant improvement in neuropathic symptoms. The mean decrease in the Small Fiber Neuropathy Symptom Inventory (SFNSL) score was 9.1 points, demonstrating a substantial reduction in pain and discomfort.
Metabolic Health: Research indicates that ARA-290 improves metabolic control in patients with type 2 diabetes by enhancing insulin sensitivity and reducing inflammatory markers. This dual benefit makes ARA-290 a valuable therapeutic agent for patients with both neuropathic pain and metabolic disorders.
Tissue Repair: ARA-290 promotes angiogenesis and reduces apoptosis, aiding in the repair and regeneration of damaged tissues. This property is particularly beneficial for conditions involving chronic inflammation and tissue damage.
ARA-290 is generally well-tolerated. Common side effects include mild injection site reactions and occasional headaches. No major adverse events have been reported, making ARA-290 a safe option for long-term use in managing neuropathic pain and metabolic health issues.
Molecular Medicine, 2022; Peptide Sciences, 2023; ResearchGate, 2023.
Read More: https://molmed.biomedcentral.com/articles/10.1186/s/molmed-2018-0012, https://www.peptidesciences.com/ara-290, https://www.researchgate.net/publication/325134276_ARA_290_in_Neuropathic_Pain
Articles
ARA290, a Peptide Derived from the Tertiary Structure of Erythropoietin, Produces Long-term Relief of Neuropathic Pain: An Experimental Study in Rats and β-Common Receptor Knockout Mice
Exogenous erythropoietin inhibits development of allodynia in experimental painful neuropathy because of its antiinflammatory and neuroprotective properties at spinal, supraspinal, and possibly peripheral sites. The authors assess the effect of a nonhematopoietic erythropoietin analog, ARA290, on tactile and cold allodynia in a model of neuropathic pain (spared nerve injury) in rats and mice lacking the […]
ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception
ARA 290 is an erythropoietin-derived polypeptide that possesses analgesic and tissue protective effect in many diseases such as diabetes and cancer. The analgesic effect of ARA 290 is mediated by its anti-inflammatory and immunomodulatory functions, or more specifically, by targeting the innate repair receptor (IRR) to down-regulate inflammation to alleviate neuropathic pain.
Doctor's Reviews
ARA 290: Unleashing the Power of Regeneration and Wellness | Elite Health Online
It is derived naturally from a protein called erythropoietin. Has protective effects on nerve cells and reduces inflammation. Ara 290 has an excellent safety profile and is well-tolerated by patients.
ARA 290
Are you or a loved one struggling with chronic pain and inflammation? Discover ARA 290, a groundbreaking peptide derived from a natural hormone that can offer relief from pain and inflammation, helping you lead a more comfortable life.
